Leukotriene antagonism in asthma and rhinitis

Respiratory Medicine

Volumn 92, Issue 6, 1998, Pages 795-809

  Lane, S J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; DISEASE CONTROL; DRUG EFFICACY; DRUG POTENCY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RHINITIS;

EID: 0031876485     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90380-8     Document Type: Review

References (150)

1. Creticos P. Allergic rhinitis. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Oxford, U.K.: Blackwell Scientific, 1995; 1394-1414.
2. Watson WTA, Becker AB, Simons FER. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airways responsiveness. J Allergy Clin Immunol 1993; 91: 97-101.
3. Enarson DA, Vedal S, Schulzer M, Chan-Yeung M. Asthma, asthma-like symptoms, chronic bronchitis and the degree of bronchial hyperresponsiveness in epidemiological surveys. Am Rev Respir Dis 1987; 136: 613-617.
4. Hogg JC, James AL, Pare PD. Evidence for inflammation in asthma. Am Rev Respir Dis 1991; 143 (Suppl): s39-s42.
5. Djukanovic R, Roche WR, Wilson JW et al. Mucosa inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-457.
6. Jeffery PK, Nelson FC, Wardlaw A, Kay AB, Collins JV. Ultrastructural analysis of bronchial-mucosa in asthma. J Pathol 1987; 151A: 58.
7. Howarth PH, Bradding P, Feather I. Wilson S, Church MK, Holgate ST. Mucosal cytokine expression in allergic rhinitis. Int Arch Allergy Immunol 1995; 107: 390-391.
8. Djukvanovic R, Wilson SJ, Howarth PH. Pathology of rhinitis and bronchial asthma. Clin Exp Allergy 1996; 91 (Suppl.): s44-s51.
9. Barnes PJ. Drug therapy - inhaled glucocorticoids for asthma. N Engl J Med 1995; 332: 868-875
10. International Rhinitis Working Group. International report on the diagnosis and management of rhinitis. Allergy 1994; 49 (Suppl): s1-s34.
11. Reiss TF, Sorkness CA, Stricker W et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52: 45-48.
12. Kelleway CH, Trethewie WR. The liberation of a slow reacting smooth muscle stimulating substance of anaphylaxis. Quart J Exp Physiol 1940; 30: 124-145.
13. Morris HR, Taylor GW, Piper PJ. Structure of slow reacting substance of anaphylaxis from guinea pig lung. Nature 1980; 285: 104-106.
14. Lewis RA. Austen KF, Drazen JM. Slow reacting substance of anaphylaxis: identification of leukotriene C-1 and D from human and rat sources. Proc Natl Acad Sci U.S.A. 1980; 77: 3712-3714.
15. Samuelsson B, Hammarstrom S, Murphy RC. Leukotrienes and slow reacting substance of anaphylaxis (SRS-A). Allergy 1980; 35: 375-381.
16. Nasser SN, Lee TH. Lipid mediators - Leukotrienes, Prostanoids and platelet activating factor. In: Kay AB, ed. Allergy and Allergic Diseases. Oxford: Blackwell Science, 1996: 380-418.
17. Dixon RAF, Diehl RE, Opas E. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343: 282-284.
18. Kargman S, Rousseau P, Reid GK. Leukotriene synthesis in U937 cells expressing recombinant 5-lipoxygenase. J Lipid Mediators 1993; 7: 31-35.
19. Williams JD, Czop JK, Austen KF. Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 1984; 132: 3034-3040.
20. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U.S.A. 1983; 80: 7626-7630.
21. Feinmark SJ, Cannon PJ. Endothelial cell leukotriene C4 synthesis results from intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986; 261: 16466-16472.
22. Coleman RA, Eglen RM, Jones RL et al. Prostanoid and leukotriene receptors - a progress report from the IUPHAR Working Parties on Classification and Nomenclature. Adv Prostaglandin Thromboxane Leukotriene Res 1995; 23: 283-285.
23. Drazen JM, Austen KF, Lewis RA. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U.S.A. 1980; 77: 4354-4358.
24. Goldman DW, Goetzl EJ. Selective transduction of human polymorphonuclear leukocyte functions by subsets of receptors for leukotriene B4. J Allergy Clin Immunol 1984; 74: 373-377.
25. Dahlén S-E, Björk J, Hedqvist P et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci U.S.A. 1981; 78: 3887-3891.
26. McIntyre TM, Zimmerman GA, Prescott SM. Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc Natl Acad Sci U.S.A. 1986; 83: 2204-2208.
27. Laitinen LA, Laitinen A, Haahtela T, Vikka V, Spur BW, Lee TH. Leukotriene-E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989-990.
28. Dahlen SE, Hedqvist P, Hammaarstrom SBS. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484-486.
29. Adelroth E, Morris MM, Hargreave FE, M OBP. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315: 480-484.
30. Davidson AB, Lee TH, Scanlon PD et al. Bronchoconstrictor effects of leukotriene-E4 in normal and asthmatic subjects. Am Rev Respir Dis 1987; 135: 333-337.
31. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 1984; 39: 500-504.
32. O'Hickey SP, Arm JP, Rees PJ, Spur BW, Lee TH. The relative responsiveness to inhaled leukotriene-E4, methacholine and histamine in normal and asthmatic subjects. Eur Resp J 1988; 1: 913-917.
33. 4, methacholine and histamine. Am Rev Respir Dis 1990; 142: 1112-1118.
34. Kern R, Smith LJ, Patterson R. Characterization of the airway response to inhaled leukotriene D4 in normal subjects. Am Rev Respir Dis 1986; 131: 1127-1132.
35. Smith LJ, Greenberger PA, Patterson R. The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis 1985; 131: 368-372.
36. O'Hickey SP, Hawksworth RJ, Fong CY, Arm JP, Spur BW, Lee TH. Leuoktriene-C4, Leukotriene-D4, and leukotriene-E4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991; 144: 1053-1057.
37. Christie PE, Hawksworth R, Spur BW, Lee TH. Effect of indomethacin on leukotriene E4-induced histamine hyperresponsiveness in asthmatic subjects. Am Rev Respir Dis 1992; 146: 1506-1510.
38. Smith CM, Hawksworth RJ, Thien FCK, Christie PE, Lee TH. Urinary leukotriene-E4 in bronchial-asthma. Eur Respir J 1992; 5: 693-699.
39. Maltby NH, Taylor GW, Ritter JM. Moore K, Fuller RW, Dollery CT. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol 1990; 85: 3-9.
40. Westcott JY, Smith HR, Wenzel SE, Larsen GL, Thomas RB, Felsien D. Urinary leukotriene E4 in patients with asthma. Effect of airways reactivity and sodium cromoglycate. Am Rev Respir Dis 1991; 143: 1322-1328.
41. Christie PE, Tagari P, Ford-Hutchinson AW et al. Increased urinary LTE(4) excretion following inhalation of LTC(4) and LTE(4) in asthmatic subjects. Eur Resp J 1994; 7: 907-913.
42. Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990: 142: 112-119.
43. Wenzel SE, Westcott JY, Larsen GL. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991; 87: 540-548.
44. Manning PJ, Rokach J, Malo JL et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86: 211-220.
45. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene-E4 and 11-dehydro-thromboxane-B2 in response to bronchial provocations with allergen, aspirin, leukotriene-D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96-103.
46. Nasser SMS, Bell GS, Hawksworth RJ et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994; 49: 743-748.
47. Pliss LB, Ingenito EP, Ingram RH Jr, Pichurko B. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis 1990; 142: 73-78.
48. Smith CM, Christie PE, Hawksworth RJ, Thien F, Lee TH. Leukotriene-E4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 144: 1411-1413.
49. Kikawa Y, Miyanomae T, Inoue T et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89: 1111-1119.
50. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene-E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025-1029.
51. Christie PE, Tagari P, Ford-Hutchinson AW, Black C, Markendorf A, Lee TH. Urinary leukotriene E4 after lysine-aspirin inhalation in asthmatic subjects. Am Rev Respir Dis 1992; 146: 1531-1534.
52. Sladek K, Dworski R, Soja J, Sheller JR, Nizankowska E, Oates JA. Eicosanoids in bronchoalveolar lavage fluid of aspirin-tolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940-946.
53. Picado C, Ramis I, Rosello J et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145: 65-69.
54. Lam S, Chan H, Leriche JC, Chanyeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81: 711-717.
55. 4 in brochoalveolar lavage in bronchial-asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19-26.
56. Drazen JM, O'Brien J, Sparrow D et al. Recovery of leukotriene-E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146: 104-108.
57. Naclerio RM, Baroody FM, Togias AG. The role of leukotrienes in allergic rhinitis - a review. Am Rev Respir Dis 1991; 143 (Suppl): S91-S95.
58. Miadonna A, Tedeschi A, Leggieri E. Behaviour and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am Rev Respir Dis 1987; 136: 357-62.
59. Creticos PS, Peters SP, Adkinson NF et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Eng J Med 1984; 310: 1626-1630.
60. Georgitis JW, Stone BD, Gottschlich G. Nasal inflammatory mediator release in ragweed allergic rhinitis - correlation with cellular influx into nasal secretions. Int Arch Allergy Appl Immunol 1991; 96: 231-237.
61. Wilson SJ, Lau LCK, Howarth PH. Mediator and cellular events in naturally ocurring seasonal allergic rhinitis. Clin Exp Allergy 1994; 24: 997A.
62. Skoner DP, Lee L Doyle WJ. Nasal physiology and inflammatory mediators during natural pollen exposure. Ann Allergy 1990; 65: 206-210.
63. 4) release in respiratory mucosa during natural exposure to ragweed in ragweed sensitive children. Ped Research 1987; 21: A506-A506.
64. Knani J, Campbell A, Enander I. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90: 880.
65. Bentley AM, Jacobson MR, Cumberworth V et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis - increases in activated eosinophils and epithelial mast-cells. J Allergy Clin Immunol 1992; 89: 877-883.
66. Durham SR, Ying S, Varney VA. Cytokine mRNA expression of IL-2, IL-4, IL-5 and GM-CSF in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 1992; 148: 2390-2394.
67. Naclerio RM, Baroody FM, Kagey-Sobottka A, Lichtenstein LM. Basophils and Eosinophils in allergic rhinitis. J Allergy Clin Immunol 1994; 94: 1303-1309.
68. Bisgaard H, Olsson, Bende M. Effect of leukotriene D4 on nasal mucosal blood-flow, nasal airway-resistance and nasal secretions in humans. Clin Allergy 1986; 16: 289-297.
69. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene-D4 in allergic rhinitis. Ann Allergy 1988; 60: 537-540.
70. Israel E, Rubin P, Kemp JP et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Medic 1993; 119: 1059-1066.
71. Spector SL, Smith LJ, Glass M and Accolate Asthma Trialists Group. Effects of 6 weeks therapy with oral doses of ICI 204 219, a leukotriene D4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-623.
72. Augstein J, Farmer JB, Lee TB. Selective inhibitor of slow reacting substance of anaphylaxis. Nature 1973; 254: 215-217.
73. Lee TH, Walport MJ, Wilkinson AH, Turner-Warwick M, Kay AB. Slow reacting substance if anaphylaxis antagonist FPL 55712 in chronic asthma. Lancet 1981; ii: 304-305.
74. Jones TR, Young R, Champion E et al. L-649 923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-gamma-hydroxy- beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonist. Can J Physiol Pharmacol 1986; 64: 1068-1075.
75. Barnes N, Piper PJ, Costello J. The effect of an oral leukotriene antagonist L-649 923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 1987; 79: 816-821.
76. Phillips GD, Rafferty P, Robinson C, Holgate ST, Dose-related antagonism of leukotriene-D4-induced bronchoconstriction by po administration of Ly-171883 in nonasthmatic subjects. J Pharmacol Exp Therap 1988; 246: 732-738.
77. Wood-Baker R, Phillips GD, Lucas RA, Turner GA, Holgate ST. The effect of inhaled Ly-170680 on leukotriene-D4-induced bronchoconstriction in healthy volunteers. Drug Invest 1991; 3: 239-247.
78. Joos GF, Kips JC, Pauwels RA, Van Der Straeten ME. The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulmon Pharmacol 1991; 4: 37-42.
79. Krell RD, Aharony D, Buckner CK et al. The preclinical pharmacology of ICI 204 219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990; 141: 978-987.
80. Kips JC, Joos GF, DeLepeleire I et al. MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Respir Dis 1991; 144: 617-621.
81. DeLepeleire I, Reiss TF, Rochette F et al. Montelukast causes prolonged, potent leukotriene D-4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Therap 1997; 61: 83-92.
82. Fuller RW, Black PN, Dollery CT. Effect of the oral leukotriene D4 antagonist LY171883 on inhaled and intradermal challenge with antigen and leukotriene D4 in atopic subjects. J Allergy Clin mmunol 1989; 83: 939-944.
83. Britton JR, Hanley SP, Tattersfield AE. The effect of an oral leukotriene D4 antagonist L-649 923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol 1987; 79: 811-816.
84. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337: 690-694.
85. O'Shaughnessy KM, Taylor IK, O'Connor B, O'Connell F, Thomson H. Potent leukotriene D4 receptor antagonist ICI 204 219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147: 1431-1435.
86. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204 219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992; 89: 1040-1045.
87. Dahlen B, Zetterstrom O, Bjorck T, Dahlen SE. The leukotriene-antagonist ICI-204219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Resp J 1994; 7: 324-331.
88. Rasmussen JB, Eriksson LO, Margolskee DJ, Tagari P, Williams VC, Andersson KE. Leukotriene-D(4) receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90: 193-201.
89. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK-and-F-104 353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-958.
90. Kumlin M, Johansson H, Larsson C et al. The leukotriene antagonist MK-0679 improves baseline pulmonary function and blocks aspirin-induced airways obstruction in aspirin-sensitive asthmatics. Am Rev Respir Dis 1992; 145: A15.
91. Israel E, Juniper EF, Callaghan JT et al. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989; 140: 1348-1353.
92. Robuschi M, Riva E, Fuccella LM et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F-104353) - a double-blind-study versus disodium-cromoglycate and placebo. Am Rev Respir Dis 1992; 145: 1285-1288.
93. Makker HK, Lau LC, Thomson HW, Binks SM, Holgate ST. The protective effect of inhaled leukotriene-D(4) receptor antagonist ICI-204 219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-1418.
94. Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O'Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4 antagonist. N Engl J Med 1990; 323: 1736-1739.
95. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Therap 1997; 62: 556-561.
96. Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast, a leukotriene receptor antagonist, inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children. J Allergy Clin Immunol 1997; 99: 1314-1314.
97. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52: 1030-1035.
98. Strek ME, Sedy J, Solway J, Jorkasky DK, Jones B, Boike SC. Pranlukast (Ultair®) inhibits cold air-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 1997; 99: 1342.
99. Ellis JL, Undem BJ. Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi. Am J Respir Crit Care Med 1994; 149: 118-122.
100. Impens N, Reiss TF, Teahan JA et al. Acute bronchodilation with an intravenously administered leukotriene- D(4) antagonist, MK-679. Am Rev Respir Dis 1993; 147: 1442-1446.
101. Hui KP, Barnes NC. Lung-function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-1063.
102. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992; 146: 358-363.
103. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on base-line pulmonary-function in aspirin-sensitive asthmatic subjects. Thorax 1993; 48: 1205-1210.
104. Smith LJ, Jorkasky DK, Carr S, Boike SC. Intravenous pranlukast (Ultair®) inhibits LTD(4)-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 1997; 99: 1341-1341.
105. 4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. Am Rev Respir Dis 1989; 140: 1336-1339.
106. Reiss TF, Altman LC, Chervinsky P et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD(4)) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-534.
107. Fujimura M, Sakamo S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87: 133-138.
108. Fish JE, Kemp JP, Lockey RF et al. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study. Clin Therap 1997; 19: 675-690.
109. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177.
110. Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving receiving zafirlukast. J Am Med Assoc 1998; 279: 455-457.
111. Wahedna I, Wisniewski AFZ, Wong CS, Tattersfield AE. Effect of multiple doses of RG 12525, an oral leukotriene D4 antagonist, in chronic asthma. Am Rev Respir Dis 1992; 145: A16.
112. Tamaoki J, Kondo M, Sakai N et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997; 155: 1235-1240.
113. Oosaki R, Mizushima Y, Kashii T, Kawasaki A, Kobayashi M. Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. Int Arch Allergy Immunol 1997; 114: 97-100.
114. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: Results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52: 523-527.
115. Grossman J, Faiferman I, Dubb JW et al. Results of the first US double-blind, placebo-controlled, multi-center clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34: 321-328.
116. Flowers BK, Proud D, Kagey-Sobotka A, Lichtenstein LM. The effect of leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990; 102: 219-224.
117. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4 receptor antagonist, ICI 2 204,219, relieves symptoms of acute seasonals rhinitis. Am J Respir Crit Care Med 1995; 151: 1734-1739.
118. Grossman J, Ratner PH, Nathan R, Adelglass J, deJong B. Pranlukast (Ultair™, SB 205312, ONO-1078), an oral leukotriene receptor antagonist, relieves symptoms in patients with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol 1997; 99: 1799.
119. Evans JF, Leville C, Mancini JA et al. 5-lipoxygenase-activating protein is the target of a quinolone class of leukotriene biosynthesis inhibitors. Mole Pharmacol 1991; 40: 22-27.
120. Garland LG, Salmon JA. Hydroxamic acids and hydroxureas as inhibitors of arachidonate 5-lipoxygenase. Drugs Future 1991; 16: 547-558.
121. Hui KP, Taylor IK, Taylor GW et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46: 184-189.
122. Friedman BS, Bel EH, Buntinx A et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.
123. Diamant Z, Timmers MC, Vanderveen H et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in-vivo. J Allergy Clin Immunol 1995; 95: 42-51.
124. Israel E, Fischer AR, Rosenberg MA et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-1451.
125. Nasser SMS, Bell GS, Foster S et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49: 749-756.
126. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1740-1744.
127. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton - a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153: 931-935.
128. Chapman KR, Friedman BS, Shingo S, Heyse J, Reiss T, Spector R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am J Respir Crit Care Med 1994; 149: A215.
129. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma - a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996; 98: 859-871.
130. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-LO inhibitor. N Engl J Med 1990; 323: 1740-1748.
131. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma - a randomized controlled trial. J Am Med Assoc 1996; 275: 931-936.
132. DuBuske LM, Grossman J, Dube LM et al. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Am J Managed Care 1997; 3: 633-640.
133. Schwartz HJ, Petty T, Dube LM, Swanson LJ, Lancaster JF. A randomised controlled trial comparing zileuton with theophylline in moderate asthma. Arch Intern Med 1998; 158: 141-148.
134. Howarth PH, Harrison K, Lau L. The influence of 5-lipoxygenase inhibition in allergic rhinitis. Int Arch Allergy Immunol 1995; 107: 423-424.
135. Ancill RJ, Takahashi Y, Kibune Y, Campbell R, Smith JR. Randomized double-blind, placebo-controlled clinical trial of a selective 5-lipoxygenase inhibitor (AA-861) for the prevention of seasonal allergic rhinitis. J Int Med Res 1990; 18: 75-88.
136. Spaeth J, Schultze V, Klimek L, Lengersdorf A, Mosges R. Azelastine reduces histamine-induced swelling of nasal-mucosa. Orl-J- Oto-Rhino-Laryngol Related Specialities 1996; 58: 157-163.
137. Fischer AR, Rosenberg MA, Lilly CM et al. Direct evidence for a role of the mast-cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94: 1046-1056.
138. Owens CA, Grundy GW. Focus on zileuton: the first FDA-approved agent of a new class of drugs for the management of asthma. Formulary 1997; 32: 455.
139. Spector SL. Management of asthma with zafirlukast-clinical experience and tolerability profile. Drugs 1996; 52: 36-46.
140. Barnes NC, deJong B, Miyamato T. Worldwide clinical experience with the first marketed leukotriene receptor antagonist. Chest 1997; 111: (Suppl.) S52-S60.
141. Sorkness CA. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy 1997; 17 (Suppl.): S50-S54.
142. Kelloway JS, Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacotherapy 1997; 31: 1012-1021.
143. Bethesda Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung and Blood Institute, National Institutes of Health, 1997.
144. Marom Z, Shelhamer JH, Bach MK, Morton, DR, Kaliner, M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-451.
145. Camp RDR, Coutts AA, Greaves MW, Kay AB, Walport MK. Response of human skin to intra-dermal injection of leukotrienes C4, D4 and B4. B J Pharmacol 1983; 80: 497-502.
146. 4) in human skin. J Invest Dermatol 1983; 80: 115-119.
147. Michelassi F, Landa L, Hill RD, Lowenstein E, Watkins WD, Petkau AJ. Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 1982; 217: 841-843.
148. Pfeffer MA, Pfeffer JM, Lewis RA, Braunwald E, Corey EJ, Austen KF. Systemic hemodynamic effects of leukotrienes C4 and D4 in the rat. Am J Physiol 1983; 244: H628-H633.
149. Badr KF, Baylis C, Pfeffer JM et al. Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rate. Circ. Res 1984; 54: 492-499.
150. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989-990.